CorMedix Inc. (CRMD) News
Follow CorMedix Inc. (CRMD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 27 public stories across 14 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
CorMedix Says It Believes 2027 DefenCath Revenue Guidance Should Be Suspended
CorMedix said it believes suspending previously issued 2027 DefenCath revenue guidance is appropriate and will defer future guidance until early 2027.
EARNINGS | Nov 12, 2026, 12:33 PM UTC
M
CorMedix to Acquire Heron Assets for $145M Cash, Stock and Up to $55M in Earn-Outs
CorMedix agreed to acquire substantially all of Heron’s assets, adding four commercial products and a development pipeline.
EQUITY | Nov 10, 2026, 10:24 PM UTC
M
Heron Therapeutics Q3 Revenue Falls 7.8%; to Sell Assets to CorMedix
Heron Therapeutics reported a 7.8% decline in third-quarter net revenue and plans to sell all its assets to CorMedix.
EQUITY | Nov 09, 2026, 01:41 PM UTC
M
CorMedix to Acquire Heron Therapeutics Assets for $145 Million and 14.6 Million Shares
CorMedix agreed to acquire substantially all of Heron Therapeutics’ assets for $145 million in cash, subject to adjustments, and 14,583,333 CorMedix shares. The deal also includes potential royalties and up to $55 millio
EQUITY | Nov 09, 2026, 01:04 PM UTC
M
CorMedix to Acquire Substantially All Heron Therapeutics Assets
The transaction adds four commercial-stage products to CorMedix’s hospital- and acute-care-focused platform. Consideration includes $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333 C
EQUITY | Nov 09, 2026, 12:17 PM UTC
M
CorMedix Q3 Results Scheduled for November 11
CorMedix is scheduled to report Q3'26 results on November 11. Revenue is estimated at 52.77 million USD and EPS at (0.11) USD; the release time is not specified.
EQUITY | Nov 04, 2026, 12:01 PM UTC
M
CorMedix Reaffirms 2026 Revenue Guidance of $325 Million to $345 Million
EARNINGS | Nov 02, 2026, 01:47 PM UTC
M
CorMedix Expects 2027 Add-On Rate to Exceed $2.37 Each Quarter
EARNINGS | Nov 02, 2026, 12:32 PM UTC
L
CorMedix Reaffirms 2026 Revenue Guidance and Reports Q3 Cash Position
CorMedix Therapeutics reaffirmed its 2026 total revenue guidance and reported its third-quarter cash position.
EARNINGS | Nov 02, 2026, 12:32 PM UTC
M
CorMedix Shares Hit 52-Week Low After DaVita Flags 2027 Reimbursement Drop
CorMedix shares fell nearly 26% on Friday, hitting a fresh 52-week low after DaVita warned that Medicare reimbursement for DefenCath could drop sharply in 2027.
EQUITY | Oct 30, 2026, 07:51 PM UTC
L
CorMedix Says FDA Accepted REZZAYO Prophylaxis sNDA for Priority Review
CorMedix said the FDA accepted its supplemental application seeking approval of REZZAYO for prophylaxis. The application has a PDUFA target date in Q1 2027.
REGULATION | Oct 19, 2026, 12:03 PM UTC
L
FDA accepts Rezzayo supplemental NDA for priority review
CorMedix announced FDA acceptance of its supplemental new drug application for Rezzayo (rezafungin) for priority review for prophylaxis of invasive fungal diseases.
REGULATION | Oct 19, 2026, 11:30 AM UTC
L
CorMedix Price Target Announced at $15.00/Share by Oppenheimer
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 10:42 AM UTC
L
CRMD cites diversified specialty pharma platform and new market opportunities
CRMD says it has evolved into a diversified specialty pharma with eight marketed products and a scalable institutional platform, citing reimbursement transition, Medicare Advantage focus, REZZAYO expansion potential, and
EQUITY | Sep 09, 2026, 06:06 PM UTC
L
CRMD: Diversified portfolio, robust cash, and new indications position the company for strong institutional growth
The company has transformed into a diversified specialty pharma with eight marketed products and a scalable institutional platform. DefenCath’s reimbursement transition and Medicare Advantage efforts are key near-term dr
EQUITY | Sep 09, 2026, 05:39 PM UTC
L
CRMD: Strong revenue growth, pipeline expansion, and financial flexibility drive continued value creation
A diversified specialty pharma business with a strong institutional focus, robust product portfolio, and scalable commercial platform is delivering sustained revenue growth and profitability. DefenCath and REZZAYO drive
EQUITY | Sep 09, 2026, 12:51 PM UTC
L
CorMedix Therapeutics to participate in Wells Fargo Healthcare Conference
CorMedix Therapeutics said senior management will participate in a fireside at the Wells Fargo Healthcare Conference.
EQUITY | Sep 01, 2026, 12:37 PM UTC
L
CRMD - CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
CRMD - CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
EQUITY | Sep 01, 2026, 12:31 PM UTC
L
CorMedix tops Q2 estimates, raises adjusted EBITDA guidance
CorMedix Inc. reported second-quarter adjusted EPS of 29 cents and revenue of $101.9 million, both above consensus, and raised adjusted EBITDA guidance while reaffirming fiscal 2026 sales guidance.
EARNINGS | Aug 13, 2026, 02:56 PM UTC
L
CorMedix surges after better-than-expected Q2 results
CorMedix Inc. (NASDAQ: CRMD) surged 23.6% after the company reported better-than-expected second-quarter financial results.
EARNINGS | Aug 13, 2026, 01:57 PM UTC
L
Cormedix Q2 revenue, EBITDA rise; guidance lifted
Cormedix reported second-quarter revenue of $101.9 million and adjusted EBITDA of $58.7 million, signed a multi-year DefenCath supply deal with another large dialysis organization, and raised full-year adjusted EBITDA gu
EARNINGS | Aug 13, 2026, 01:07 PM UTC
L
Cormedix affirms FY2026 sales guidance at $325M–$345M
Cormedix (NASDAQ: CRMD) affirms FY2026 sales guidance of $325.000M–$345.000M, compared with a $334.089M estimate, with the range unchanged from the prior outlook.
EARNINGS | Aug 13, 2026, 11:30 AM UTC
L
Cormedix Therapeutics reports Q2 2026 results and business update
Cormedix Therapeutics (CRMD) reports its second quarter 2026 financial results and provides a business update, according to TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 11:30 AM UTC
L
CRMD - CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026 - Click For R
CRMD - CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
EARNINGS | Jul 29, 2026, 12:31 PM UTC
L
CorMedix Names Elizabeth Hurlburt as Chief Operating, Commercial Officer
() -- CorMedix (CRMD) board has appointed chief operating officer, Elizabeth Hurlburt, to the newly created role of chief operating and commercial officer, the company said in a late Thursday filing. As part of this lead
EQUITY | Jul 02, 2026, 08:52 PM UTC
L
CorMedix shares are trading higher. The company announced its Audit Committee approved changing the independent public accounting firm, dism
CorMedix shares are trading higher. The company announced its Audit Committee approved changing the independent public accounting firm, dismissing CBIZ CPAs.
EQUITY | Jul 01, 2026, 05:16 PM UTC
H
Nike, Shutterstock And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling more than 100 points on Wednesday. Shares of Nike Inc (NYSE: NKE ) fell sharply in pre-market trading after the company reported fourth-quarter res
EARNINGS | Jul 01, 2026, 12:02 PM UTC